Results 191 to 200 of about 1,267,326 (360)

Minimal Important Change and Minimal Clinically Important Difference in Pain and Function With Exercise in Hip Osteoarthritis

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to estimate the minimal important change (MIC) and minimal clinically important difference (MCID) for pain and physical function in individuals with hip osteoarthritis (OA) following a physiotherapist‐guided exercise intervention.
Yareni Guerrero   +8 more
wiley   +1 more source

High Healthcare Utilization Preceding Diagnosis with Juvenile Idiopathic Arthritis

open access: yesArthritis Care &Research, Accepted Article.
Objective Though early diagnosis improves long‐term outcomes, Juvenile Idiopathic Arthritis (JIA) patients often experience prolonged, circuitous paths to diagnosis. To inform diagnostic improvement, we sought to characterize healthcare utilization in the year preceding diagnosis.
Anna Costello   +5 more
wiley   +1 more source

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. [PDF]

open access: yesBlood Adv
Chin KK   +16 more
europepmc   +1 more source

Integrating Patient‐Reported Quality Measures in SLE: Development of the American College of Rheumatology Implementation Guide

open access: yesArthritis Care &Research, Accepted Article.
Objective To support high‐quality, patient‐centered care for systemic lupus erythematosus (SLE), the American College of Rheumatology (ACR) developed evidence‐based measures incorporating clinical and patient‐reported outcomes measures (PROMs). Using the Consolidated Framework for Implementation Research (CFIR), we conducted semi‐structured interviews ...
Catherine Nasrallah   +13 more
wiley   +1 more source

Building a Framework for Sexual and Reproductive Healthcare in the Rheumatology Context: Content and Approaches

open access: yesArthritis Care &Research, Accepted Article.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial. [PDF]

open access: yesESMO Open
Fuereder T   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy